Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Digestive System Diseases

Skin and Connective Tissue Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Rare Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Adenocarcinoma

Stomach Neoplasms

Breast Neoplasms

Colorectal Neoplasms

Esophageal Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Uterine Cervical Neoplasms

Endometrial Neoplasms

Pseudomyxoma Peritonei

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Breast Diseases

Skin Diseases

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Stomach Diseases

Head and Neck Neoplasms

Esophageal Diseases

Uterine Neoplasms

Uterine Cervical Diseases

Uterine Diseases

Adenocarcinoma, Mucinous

Neoplasms, Cystic, Mucinous, and Serous

Stomach Cancer

Esophageal Cancer

Ovarian Cancer

Ovarian Epithelial Cancer

Adenocarcinoma of the Appendix

SGN-STNV

Suzanne McGoldrick, MD

This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well SGN-STNV works to treat solid tumors.

The study will have two parts. Part A of the study will find out how much SGN-STNV should be given to patients. Part B will use the dose found in Part A to find out how safe SGN-STNV is and if it works to treat certain types of solid tumors.

The study will include dose escalation (Part A) and dose expansion (Part B), with multiple disease-specific cohorts and a biology cohort in dose expansion. The biology cohort will require additional biopsies. At the completion of dose escalation, up to 5 disease specific expansion cohorts and 1 biology expansion cohort may be activated by the sponsor in consultation with the Safety Monitoring Committee (SMC). Expansion cohorts in Part B will enroll subjects with selected tumors that are eligible for enrollment in Part A. The dose(s) to be examined in Part B will be at or below the maximum tolerated dose and/or the recommended dose determined in Part A. The recommended dose and/or schedule may differ between cohorts.

A Study of SGN-STNV in Advanced Solid Tumors

A Phase 1 Study of SGN-STNV in Advanced Solid Tumors

To be summarized using descriptive statistics

ORR is defined as the proportion of subjects achieving a partial response (PR) or complete response (CR).

PFS is defined as the time from the start of any study treatment to first documentation of disease progression or to death due to any cause, whichever comes first.

OS is defined as the time from the start of any study treatment to the date of death due to any cause.

DOR is defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression or to death due to any cause, whichever comes first.

Seagen Inc.

Testicular Neoplasms

Genital Neoplasms, Male

Genital Diseases, Male

Male Urogenital Diseases

Testicular Diseases

Germ Cells Tumors

Ovarian Germ Cell Tumor

Testicular Germ Cell Tumor

Extragonadal Germ Cell Tumor

SGN-ALPV

This study will test the safety of a drug called SGN-ALPV in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease.

Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

This study will have three parts. Parts A and B of the study will find out how much SGN-ALPV should be given to participants. Part C will use the dose and schedule found in Parts A and B to find out how safe SGN-ALPV is and if it works to treat solid tumor cancers.

A Study of SGN-ALPV in Advanced Solid Tumors

A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors

Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

The proportion of participants with an objective response (OR) per investigator. A participant is determined to have an OR if, based on RECIST v1.1, the subject achieves a complete response (CR) or a partial response (PR) after initiation of treatment and at or prior to the end of treatment (EOT) disease assessment.

The time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression (based on radiographic assessments per RECIST v1.1) or death due to any cause.

The time from start of study treatment to first documentation of disease progression or death due to any cause

The time from start of study treatment to death due to any cause

The proportion of participants with ovarian cancer who have at least a 50% reduction in CA-125 value from baseline according to GCIG CA-125 criteria

The proportion of participants with ovarian cancer whose best response is a CR or PR according to the GCIG combined RECIST and CA-125 criteria

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study of SGN-STNV in Advanced Solid Tumors	NCT04665921	Carcinoma, Non-... HER2 Negative B... Ovarian Neoplas... Uterine Cervica... Endometrial Neo... Esophageal Neop... Gastroesophagea... Stomach Neoplas... Colorectal Neop... Exocrine Pancre... Appendiceal Ade... Pseudomyxoma Pe...	SGN-STNV	18 Years -	Seagen Inc.
A Study of SGN-ALPV in Advanced Solid Tumors	NCT05229900	Ovarian Neoplas... Endometrial Neo... Carcinoma, Non-... Stomach Neoplas... Gastroesophagea... Uterine Cervica... Testicular Neop...	SGN-ALPV	18 Years -	Seagen Inc.

Spots Global Cancer Trial Database for gej carcinoma